The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries

BACKGROUND: Hereditary angioedema (HAE) due to C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare, potentially fatal, bradykinin‐mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United States as an acute therapy option f...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero, T., Aberer, W., Longhurst, H.J., Maurer, M., Zanichelli, A., Perrin, A., Bouillet, L., Andresen, I., Arcoleo, F., Bova, M., Cicardi, M., Cillari, E., Montinaro, V., Marone, G., Blanchard Delauny, C., Boccon‐Gibod, I., Coppere, B., Dzviga, C., Fain, O., Goichot, B., Gompel, A., Guez, S., Jeandel, P.Y., Kanny, G., Launay, D., Maillard, H., Martin, L., Masseau, A., Ollivier, Y., Magerl, M., Baeza, M.L., Cabañas, R., Guilarte, M., Hernández, D., Hernando de Larramendi, C., Lleonart, R., Lobera, T., Marqués, L., Bangs, C., Buckland, M., Grigoriadou, S., Helbert, M., Lorenzo, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575527/
https://www.ncbi.nlm.nih.gov/pubmed/28370444
http://dx.doi.org/10.1111/jdv.14251

Ejemplares similares

Ejemplares similares